Diabetic foot ulcers (DFUs) represent a significant global health challenge, affecting an estimated 19 million individuals worldwide. In India, where the prevalence of diabetes continues to rise, these chronic wounds contribute to severe morbidity, with nearly half of patients experiencing infections and approximately 20% of moderate to severe cases progressing to lower-limb amputation. Alarmingly, the five-year mortality rate for patients with DFUs is around 30%, increasing to 70% for those who undergo amputation.

Current Therapeutic Limitations

Conventional DFU management largely focuses on slowing disease progression, preventing infection, and alleviating symptoms through wound care, offloading, and pharmacological interventions. However, these approaches often fail to address the underlying impairments in tissue regeneration, chronic inflammation, and microvascular dysfunction, which are critical obstacles to wound healing.

Regenerative Potential of Stem Cells and Growth Factors

Recent research has highlighted the therapeutic promise of stem cells and growth factors in promoting DFU healing. A 2025 review by Metwaly et al. in Diabetes Research and Clinical Practice evaluated mesenchymal stem cells, mononuclear cells, pluripotent stem cells, and several key growth factors—including epidermal growth factor, platelet-derived growth factor, vascular endothelial growth factor, and platelet-rich plasma—for their efficacy in DFU treatment. The analysis demonstrated that these interventions can enhance angiogenesis, modulate chronic inflammation, and restore the defective extracellular matrix characteristic of diabetic wounds.

Mesenchymal stem cells, in particular, exert regenerative effects by stimulating new blood vessel formation, promoting skin repair, and regulating immune responses that otherwise inhibit healing. Similarly, growth factors facilitate fibroblast chemotaxis, endothelial cell activation, and controlled inflammatory signalling, collectively accelerating tissue repair and reducing ulcer chronicity.

Evidence and Limitations

While the accumulating body of research indicates significant improvements in wound closure and a potential reduction in amputation risk, most clinical studies remain limited by small sample sizes, short follow-up periods, and inconsistent protocols regarding stem cell or growth factor formulations and delivery methods. These factors constrain the generalisability of current findings and impede broader clinical adoption.

Future Directions

To fully integrate regenerative therapies into routine DFU management, standardised, clinically validated protocols must be developed and assessed through larger, long-term studies. Such efforts would provide robust evidence for the safety and efficacy of stem cell and growth factor therapies, offering clinicians a reliable framework to implement these innovative approaches.

Conclusion

The application of stem cells and growth factors represents a promising frontier in the treatment of diabetic foot ulcers. By enhancing angiogenesis, modulating inflammation, and supporting tissue regeneration, these therapies have the potential to improve healing outcomes and substantially reduce the risk of lower-limb amputation. Continued research and standardisation of treatment protocols are essential to translate these advances into widespread clinical practice, particularly in countries like India, where the burden of diabetes-related complications remains substantial.